# Nina Capital

Nina Capital is a Venture Capital based in Barcelona, Spain.

## Overview

- **Organization type:** Venture Capital
- **Headquarters:** Barcelona, Spain
- **Region:** Europe
- **Address:** C. Tuset 20, 5, Barcelona, Spain 08006
- **Founded:** 2019
- **Assets under management:** Undisclosed
- **Website:** www.nina.capital
- **LinkedIn:** https://www.linkedin.com/company/ninacapital

## Regulatory record

- **Reports private funds:** No

## About

Nina Capital is a specialized venture capital firm investing exclusively at the intersection of healthcare and technology. It backs need-driven founders in healthcare transformation powered by information technology, from pre-seed to seed+, and can lead rounds or coinvest. It invests in healthcare tools and medical devices and does not invest in drugs and vaccines.

## Sectors

- Digital Health
- AI/ML

## Offices

- 425 Page Mill Rd, Palo Alto, CA, US 94306

## People

- Marta G. Zanchi — Founder, Managing Partner
- Marc Subirats — General Partner
- Sebastian Anastassiou — Partner
- Yahel Halamish — Partner, Head of Investor Relations

## Questions

### Who runs investment decisions at Nina Capital?

Marta G. Zanchi, the founder and managing partner, leads the investment team alongside general partner Marc Subirats and partners Sebastian Anastassiou and Yahel Halamish. The partnership group is supported by a network of external investment advisors and venture partners with deep health-tech and clinical backgrounds. Final investment decisions are made by this core team out of the firm's Barcelona headquarters.

### Does Nina Capital invest in therapeutics or medical devices?

No. The firm is explicit that it does not invest in drugs, vaccines, or traditional regulated medical devices. Its mandate is restricted to healthcare transformation powered by information technology — software, data platforms, and AI-native clinical tools. Founders building novel molecules or hardware-dependent Class III devices fall outside the firm's scope.

### What is Nina Capital's geographic focus?

The firm invests across Europe, the United States, Israel, Canada, and Australia, with Europe serving as its operational and cultural home base. A US office on Page Mill Road in Palo Alto gives it direct proximity to Silicon Valley co-investors and portfolio companies. While the team is pan-regional in sourcing, its partnership meetings and core decision-making remain centralized in Barcelona.

### How does Nina Capital source its health-tech pipeline?

The firm runs a structured internship and fellowship program that draws visiting analysts from top-tier technical and medical universities — including Stanford, Harvard, Cambridge, EPFL, Wharton, and IESE — with alumni placed across the global health-tech ecosystem. This academic network doubles as an early-warning sourcing engine for need-driven founders emerging from university labs and clinical settings. In addition, the firm's venture partners and investment advisors on the US coasts and in Milan extend its origination reach.

### What checks does the firm write at the seed stage?

Initial ticket sizes span €200,000 to €1,500,000. These are preseed and seed checks, with capacity to follow on in subsequent rounds. The wide range reflects the firm's willingness to anchor very early rounds in Europe or participate as a smaller co-investor in larger US-led seed syndicates, depending on the founder's need and the round composition.

## Related profiles

- [Nimbus Ventures](https://altss.com/profile/nimbus-ventures)
- [Nine Four Ventures](https://altss.com/profile/nine-four-ventures)

---

Last updated: 2026-08-11T15:07:34.613Z

Canonical page: https://altss.com/profile/nina-capital

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology